Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.

doi:10.1016/j.ejca.2013.10.002

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.

European journal of cancer (Oxford, England : 1990) - 1 Jan 2014

Gelderblom H, Blay J Y, Seddon B M, Leahy M, Ray-Coquard I, Sleijfer S, Kerst J M, Rutkowski P, Bauer S, Ouali M, Marreaud S, van der Straaten R J H M, Guchelaar H-J, Weitman S D, Hogendoorn P C W, Hohenberger P

Abstract excerpt

AIM: Brostallicin is a DNA minor groove binder that has shown activity in patients with soft tissue sarcoma (STS) failing first-line therapy. The present study assessed the safety and efficacy of first-line brostallicin in patients with advanced or metastatic STS >60 years or not fit enough to receive combination chemotherapy. A prospective explorative pharmacogenetic analysis was undertaken in parallel. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Disease-Free Survival

Share to Doxorubicin

Share to Drug Administration Schedule

Share to Guanidines

Share to Pyrroles

Share to Sarcoma

Source

Open in PubMed

Identifiers

PMID: 24215845
DOI: 10.1016/j.ejca.2013.10.002

Genes

GSTA1
STS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.PMID 24215845Read ↗

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.Semantic proximity Read ↗

Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review of 2010-2020Semantic proximity Read ↗

Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.Semantic proximity Read ↗

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients.Semantic proximity Read ↗

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activitySemantic proximity Read ↗

Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma.Semantic proximity Read ↗

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.Semantic proximity Read ↗

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.Semantic proximity Read ↗

Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients.Semantic proximity Read ↗

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.Semantic proximity Read ↗

Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours.Semantic proximity Read ↗

Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.